STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 146992

TO:	From:
Marcela Cordero Garcia **Location: REM-3C18** **Art Unit: 1654** **Friday, March 18, 2005** **Case Serial Number: 10/780905**	**Mary Jane Ruhl** **Location: Biotech-Chem Library** **Remsen 1-A-62** **Phone: 571-272-2524** **maryjane.ruhl@uspto.gov**

Search Notes

Examiner Cordero Garcia,

Here are the results for your recent search request.

Please feel free to contact me if you have any questions about these results.

Thank you for using STIC services. We appreciate the opportunity to serve you.

Sincerely,

Mary Jane Ruhl
Technical Information Specialist
STIC
Remsen 1-A-62
Ext. 22524

STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact ***the searcher or contact***:

Mary Hale, Information Branch Supervisor
Remsen Bldg. 01 D86
571-272-2507

Voluntary Results Feedback Form

- *I am an examiner in Workgroup:* ☐ *Example: 1610*
- *Relevant prior art **found**, search results used as follows:*
  - ☐ 102 rejection
  - ☐ 103 rejection
  - ☐ Cited as being of interest.
  - ☐ Helped examiner better understand the invention.
  - ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
  (journal articles, conference proceedings, new product announcements etc.)

- *Relevant prior art **not found:***
  - ☐ Results verified the lack of relevant prior art (helped determine patentability).
  - ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC-Biotech-Chem Library Remsen Bldg.

FOR OFFICIAL USE ONLY

ACCESS DB # 146992
PLEASE PRINT CLEARLY

147604

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: MARCELA CORDERO GARCIA Examiner #: 80381 Date: 3/7/05
Art Unit: 1654 Phone Number: 2-2939 Serial Number: 10/780,905
Location (Bldg/Room#): REM 3C35 (Mailbox #): 3C18 Results Format Preferred (circle): PAPER DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: SEE BIB D.S.

Inventors (please provide full names): "

Earliest Priority Date: 2/18/03

Search Topic:
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only ***Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.***

PLEASE SEARCH THE METHOD OF CLM 1 WITH SECRETASE INHIBITOR L-685,458, WHICH HAS THE FOLLOWING STRUCTURE (PLEASE SEARCH MARPAT ALSO)

Inhibitor	Structure
L-685,458	

292632-98-5

IF NO HITS, PLEASE SEARCH CLM 4. (PLEASE SEARCH MARPAT ALSO)

THANKS,

Marcela

****

STAFF USE ONLY

Searcher: _____
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: _____
Date Completed: _____
Searcher Prep & Review Time: _____
Online Time: _____

Type of Search

_____ NA Sequence (#)
_____ AA Sequence (#)
_____ Structure (#)
_____ Bibliographic
_____ Litigation
_____ Fulltext
_____ Other

Vendors and cost where applicable

_____ STN _____ Dialog
_____ Questel/Orbit _____ Lexis/Nexis
_____ Westlaw _____ WWW/Internet
____ In-house sequence systems
___ Commercial ___ Oligomer ____ Score/Length
___ Interference ___ SPDI ____ Encode/Transl
_____ Other (specify)

```
=> d his ful

     (FILE 'HOME' ENTERED AT 10:55:00 ON 18 MAR 2005)

     FILE 'REGISTRY' ENTERED AT 10:55:08 ON 18 MAR 2005
L1            1 SEA ABB=ON  292632-98-5/RN — see Structure search, yellow tab, for structure

     FILE 'HCAPLUS' ENTERED AT 10:55:22 ON 18 MAR 2005
L2           35 SEA ABB=ON  L1 OR L(W)685(W)458 OR L(W)685458
L3            5 SEA ABB=ON  L2 AND ?METHOD?
L4            2 SEA ABB=ON  L3 AND (PRD<20030218 OR PD<20030218)

     FILE 'MARPAT' ENTERED AT 10:56:55 ON 18 MAR 2005
L5            0 SEA ABB=ON  L1 OR L(W)685(W)458 OR L(W)685458
L6            0 SEA ABB=ON  292632-98-5/RN
L7            0 SEA ABB=ON  292632-98-5
L8            0 SEA ABB=ON  292632-98-5/RN
L9            0 SEA ABB=ON  L(W)685(W)458 OR L(W)685458   0 cits from Marpat

     FILE 'HCAPLUS' ENTERED AT 10:58:22 ON 18 MAR 2005
                SELECT RN L4 1-2

     FILE 'REGISTRY' ENTERED AT 10:59:14 ON 18 MAR 2005
L10          22 SEA ABB=ON  (292632-98-5/BI OR 338454-52-7/BI OR 26305-03-3/BI
                OR 290315-45-6/BI OR 29169-91-3/BI OR 300865-85-4/BI OR
                323580-60-5/BI OR 500726-06-7/BI OR 500726-07-8/BI OR 500726-08
                -9/BI OR 500856-86-0/BI OR 500856-87-1/BI OR 500856-88-2/BI OR
                500856-89-3/BI OR 500856-90-6/BI OR 500857-05-6/BI OR 500857-06
                -7/BI OR 500857-07-8/BI OR 500857-08-9/BI OR 504428-17-5/BI OR
                75621-03-3/BI OR 82473-24-3/BI)

     FILE 'HCAPLUS' ENTERED AT 10:59:19 ON 18 MAR 2005
L11           2 SEA ABB=ON  L4 AND L10   2 cits from CA Plus
```

(FYI note: Claim 4 compd. has R groups internal to structure, ∴ cannot be searched w/o further definition of those groups.

MJR

```
=> d que stat l11
L1             1 SEA FILE=REGISTRY ABB=ON  292632-98-5/RN
L2            35 SEA FILE=HCAPLUS ABB=ON  L1 OR L(W)685(W)458 OR L(W)685458
L3             5 SEA FILE=HCAPLUS ABB=ON  L2 AND ?METHOD?
L4             2 SEA FILE=HCAPLUS ABB=ON  L3 AND (PRD<20030218 OR PD<20030218)
L10           22 SEA FILE=REGISTRY ABB=ON  (292632-98-5/BI OR 338454-52-7/BI OR
                 26305-03-3/BI OR 290315-45-6/BI OR 29169-91-3/BI OR 300865-85-4
                 /BI OR 323580-60-5/BI OR 500726-06-7/BI OR 500726-07-8/BI OR
                 500726-08-9/BI OR 500856-86-0/BI OR 500856-87-1/BI OR 500856-88
                 -2/BI OR 500856-89-3/BI OR 500856-90-6/BI OR 500857-05-6/BI OR
                 500857-06-7/BI OR 500857-07-8/BI OR 500857-08-9/BI OR 504428-17
                 -5/BI OR 75621-03-3/BI OR 82473-24-3/BI)
L11            2 SEA FILE=HCAPLUS ABB=ON  L4 AND L10

=> d ibib abs hitstr l11 1-2

L11  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2003:579517  HCAPLUS
DOCUMENT NUMBER:          139:272774
TITLE:                    The Mechanism of γ-Secretase: Multiple Inhibitor
                          Binding Sites for Transition State Analogs and Small
                          Molecule Inhibitors
AUTHOR(S):                Tian, Gaochao; Ghanekar, Smita V.; Aharony, David;
                          Shenvi, Ashok B.; Jacobs, Robert T.; Liu, Xiaodong;
                          Greenberg, Barry D.
CORPORATE SOURCE:         Department of Lead Discovery, AstraZeneca
                          Pharmaceuticals, Wilmington, DE, 19850, USA
SOURCE:                   Journal of Biological Chemistry (2003),
                          278(31), 28968-28975
                          CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER:                American Society for Biochemistry and Molecular
                          Biology
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   Transition state analogs pepstatin Me ester (PME) and L685458 have been
     shown to inhibit γ-secretase non-competitively (Tian, G.,
     Sobotka-Briner, C., Zysk, J., Liu, X., Birr, C., Sylvester, M. A.,
     Edwards, P. D., Scott, C. W., and Greenberg, B. D. (2002) J. Biol. Chemical
     277, 31499-31505). This unusual kinetics suggests phys. separation of the
     sites for substrate binding and catalysis with binding of the transition
     state analogs to the catalytic site and not to the substrate binding site.
     Methods of inhibitor cross-competition kinetics and competition
     ligand binding were utilized to address whether non-transition state small
     mol. inhibitors, which also display non-competitive inhibition of
     γ-secretase, inhibit the enzyme by binding to the catalytic site as
     well. Inhibitor cross-competition kinetics indicated competitive binding
     between the transition state analogs PME and L685458 and between small
     mol. arylsulfonamides and benzodiazepines, but non-competitive binding
     between the transition state analogs and the small mol. inhibitors. These
     results were indicative of two inhibitor binding sites, one for transition
     state analogs and the other for non-transition state small mol.
     inhibitors. The presence of two inhibitor binding sites for two different
     classes of inhibitors was corroborated by results from competition ligand
     binding using [3H]L685458 as the radioligand. Although L685458 and PME
     displaced the radioligand at the same concns. as for enzyme inhibition,
     arylsulfonamides and benzodiazepines did not displace the radioligand at
     their Ki values, a result consistent with the presence of two inhibitor
     binding sites. These findings provide useful insights into the catalytic
     and regulatory mechanisms of γ-secretase that may facilitate the
     design of novel γ-secretase inhibitors.
```

IT **29169-91-3 290315-45-6 292632-98-5, L685458**
504428-17-5
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor cross-competition kinetic anal. indicates γ-secretase has sep. binding sites for transition state isosteres and for small mol. inhibitors)

RN 29169-91-3 HCAPLUS
CN L-Alaninamide, N-(3-methyl-1-oxobutyl)-L-valyl-L-valyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-[(1S,2S)-2-hydroxy-4-methoxy-1-(2-methylpropyl)-4-oxobutyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—Bu-i

RN 290315-45-6 HCAPLUS
CN Benzenebutanoic acid, 2-[(1R)-1-[[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl)amino]ethyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 292632-98-5 HCAPLUS
CN L-Phenylalaninamide, N-[(2R,4R,5S)-5-[[(1,1-dimethylethoxy)carbonyl]amino]-4-hydroxy-1-oxo-6-phenyl-2-(phenylmethyl)hexyl]-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 504428-17-5 HCAPLUS
CN Benzeneacetamide, N-[(1R)-2-[[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **338454-52-7**, γ-Secretase
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(inhibitor cross-competition kinetic anal. indicates γ-secretase has sep. binding sites for transition state isosteres and for small mol. inhibitors)
RN 338454-52-7 HCAPLUS
CN γ-Secretase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:173459 HCAPLUS
DOCUMENT NUMBER: 138:217451
TITLE: Preparation, substrate specificity, and therapeutic uses of human γ3 protease involved in processing of amyloid precursor protein
INVENTOR(S): Crouthamel, Ming-Chih; Gardell, Stephen J.; Huang, Qian; Lai, Ming-Tain; Li, Yueming

PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018050	A1	20030306	WO 2002-US26969	20020808 <--
W: CA, JP, US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
EP 1427439	A1	20040616	EP 2002-768689	20020808 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.: US 2001-311410P P 20010810 <--
WO 2002-US26969 W 20020808 <--

AB The invention provides γ3 protease, a novel aspartyl class protease that is capable of taking part in the processing of amyloid precursor protein (APP) to Aβ peptide. The γ3 protease may be involved in the development and/or progression of Alzheimer's disease. It has a Mr of 60-120 kDa on gel filtration, and its activity is inhibited by pepstatin A but not by L685,458 (a known γ-secretase inhibitor) with a pH optimum of 6.0. γ3 Protease cleaves amyloid precursor protein, as well as artificial substrates incorporating portions of APP695, at the same or similar sites as γ-secretase, but can be distinguished from the known γ-secretase activity involving presenilin-1 and presenilin-2. **Methods** of assaying γ3 protease and identifying potential inhibitors, useful in the prevention or treatment of Alzheimer s disease, are disclosed.

IT **500856-89-3**
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; preparation, substrate specificity, and therapeutic uses of human γ3 protease involved in processing of amyloid precursor protein)
RN 500856-89-3 HCAPLUS
CN 597-695-Amyloid precursor protein APP695 [methionyl] (human) fusion protein with FLAG peptide (synthetic) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **500856-86-0 500856-87-1 500856-88-2**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; preparation, substrate specificity, and therapeutic uses of human γ3 protease involved in processing of amyloid precursor protein)
RN 500856-86-0 HCAPLUS
CN 597-695-Amyloid precursor protein APP695 (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 500856-87-1 HCAPLUS
CN L-Threonine, L-α-aspartyl-L-alanyl-L-α-glutamyl-L-phenylalanylglycyl-L-histidyl-L-α-aspartyl-L-serylglycyl-L-phenylalanyl-L-α-glutamyl-L-valyl-L-arginyl-L-histidyl-L-glutaminyl-L-lysyl-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-L-alanyl-L-α-glutamyl-L-α-aspartyl-L-valylglycyl-L-seryl-L-asparaginyl-L-

lysylglycyl-L-alanyl-L-isoleucyl-L-isoleucylglycyl-L-leucyl-L-methionyl-L-valylglycylglycyl-L-valyl-L-valyl-L-isoleucyl-L-alanyl-L-threonyl-L-valyl-L-isoleucyl-L-valyl-L-isoleucyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 500856-88-2 HCAPLUS
CN 597-695-Amyloid precursor protein APP695 [methionyl] (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **26305-03-3**, Pepstatin A
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibition of γ3 protease by; preparation, substrate specificity, and therapeutic uses of human γ3 protease involved in processing of amyloid precursor protein)
RN 26305-03-3 HCAPLUS
CN L-Alaninamide, N-(3-methyl-1-oxobutyl)-L-valyl-L-valyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-N-[(1S)-1-[(1S)-2-carboxy-1-hydroxyethyl]-3-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **292632-98-5 300865-85-4 500726-06-7 500726-07-8 500726-08-9**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(lack of γ3 protease inhibition by and purification in presence of; preparation, substrate specificity, and therapeutic uses of human γ3 protease involved in processing of amyloid precursor protein)
RN 292632-98-5 HCAPLUS
CN L-Phenylalaninamide, N-[(2R,4R,5S)-5-[[(1,1-dimethylethoxy)carbonyl]amino]-4-hydroxy-1-oxo-6-phenyl-2-(phenylmethyl)hexyl]-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 300865-85-4 HCAPLUS
CN L-Isoleucine, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-(3R,4S,5S)-4-amino-2,2-difluoro-3-hydroxy-5-methylheptanoyl-L-valyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500726-06-7 HCAPLUS
CN L-Isoleucine, N-(bromoacetyl)-L-valyl-(3R,4S,5S)-4-amino-2,2-difluoro-3-hydroxy-5-methylheptanoyl-L-valyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500726-07-8 HCAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-, (2S,5S,9R,10S,13S)-8,8-difluoro-9-hydroxy-17,17-dimethyl-5,13-bis(1-methylethyl)-2,10-bis[(1S)-1-methylpropyl]-4,7,12,15-tetraoxo-16-oxa-3,6,11,14-tetraazaoctadec-1-yl ester, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 500726-08-9 HCAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-, (2S,5S,9R,10S,13S)-16-bromo-8,8-difluoro-9-hydroxy-5,13-bis(1-methylethyl)-2,10-bis[(1S)-1-methylpropyl]-4,7,12,15-tetraoxo-3,6,11,14-tetraazahexadec-1-yl ester, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





IT **500856-90-6**
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(nucleotide sequence; preparation, substrate specificity, and therapeutic uses of human γ3 protease involved in processing of amyloid precursor protein)
RN 500856-90-6 HCAPLUS
CN DNA (synthetic human 597-695-amyloid precursor protein APP695 [methionyl] fusion protein with synthetic FLAG peptide-specifying) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **75621-03-3**, CHAPS **82473-24-3**, CHAPSO
RL: NUU (Other use, unclassified); USES (Uses)
(preparation of γ3 protease from biol. membranes in presence of; preparation, substrate specificity, and therapeutic uses of human γ3 protease involved in processing of amyloid precursor protein)
RN 75621-03-3 HCAPLUS
CN 1-Propanaminium, N,N-dimethyl-N-(3-sulfopropyl)-3-[[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82473-24-3 HCAPLUS
CN 1-Propanaminium, 2-hydroxy-N,N-dimethyl-3-sulfo-N-[3-[[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]propyl]-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **500857-05-6**, 1: PN: WO03018050 SEQID: 1 unclaimed DNA
500857-07-8 500857-08-9, 9: PN: WO03018050 SEQID: 9 unclaimed DNA
RL: PRP (Properties)
(unclaimed nucleotide sequence; preparation, substrate specificity, and therapeutic uses of human γ3 protease involved in processing of amyloid precursor protein)
RN 500857-05-6 HCAPLUS
CN 1: PN: WO03018050 SEQID: 1 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 500857-07-8 HCAPLUS
CN DNA, d(G-G-A-A-T-T-C-C-A-T-A-T-G-G-A-T-G-C-A-G-A-A-T-T-C-C-G-A-C-A-T-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 500857-08-9 HCAPLUS
CN 9: PN: WO03018050 SEQID: 9 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **500857-06-7**
RL: PRP (Properties)
(unclaimed protein sequence; preparation, substrate specificity, and therapeutic uses of human γ3 protease involved in processing of amyloid precursor protein)
RN 500857-06-7 HCAPLUS
CN 2: PN: WO03018050 SEQID: 2 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **323580-60-5**
RL: PRP (Properties)
(unclaimed sequence; preparation, substrate specificity, and therapeutic uses of human γ3 protease involved in processing of amyloid precursor protein)
RN 323580-60-5 HCAPLUS
CN L-Lysine, L-α-aspartyl-L-tyrosyl-L-lysyl-L-α-aspartyl-L-α-aspartyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **338454-52-7P**, γ-Secretase
RL: ANT (Analyte); CAT (Catalyst use); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(γ3 protease; preparation, substrate specificity, and therapeutic uses of human γ3 protease involved in processing of amyloid precursor protein)
RN 338454-52-7 HCAPLUS
CN γ-Secretase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT